1. 2018
  2. Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab

    Gil Awada (Speaker), Ibrahim Özdemir (Contributor), Julia Katharina Schwarze (Contributor), Emma Daeninck (Contributor), Odrade Gondry (Contributor), Yanina Jansen (Contributor), Teofila Seremet (Contributor), Marleen Keyaerts (Contributor), Hendrik Everaert (Contributor), Bart Neyns (Contributor)
    14 Dec 2018

    Activity: Talk or presentationTalk or presentation at a conference

  3. Correlation of baseline 18F-FDG-PET/CT parameters with the outcome of advanced melanoma patients treated with the pd-1 blocking monoclonal antibody pembrolizumab

    Odrade Gondry (Speaker), Ibrahim Özdemir (Contributor), Yanina Jansen (Contributor), Gil Awada (Contributor), Julia Katharina Schwarze (Contributor), Teofila Seremet (Contributor), Hendrik Everaert (Contributor), Bart Neyns (Contributor), Marleen Keyaerts (Contributor)
    19 Oct 2018

    Activity: Talk or presentationTalk or presentation at a workshop/seminar

ID: 108744